Home Cart Sign in  
Chemical Structure| 14631-08-4 Chemical Structure| 14631-08-4

Structure of 14631-08-4

Chemical Structure| 14631-08-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 14631-08-4 ]

CAS No. :14631-08-4
Formula : C4H5ClN4
M.W : 144.56
SMILES Code : NC1=NC(Cl)=NC=C1N
MDL No. :MFCD00047355
InChI Key :QDUJVEOOSNUDDW-UHFFFAOYSA-N
Pubchem ID :84565

Safety of [ 14631-08-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 14631-08-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 35.85
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

77.82 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.85
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.14
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.31
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.63
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.28
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.19

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.32
Solubility 6.95 mg/ml ; 0.0481 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.33
Solubility 6.75 mg/ml ; 0.0467 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.53
Solubility 4.3 mg/ml ; 0.0297 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.08 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.9

Application In Synthesis of [ 14631-08-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 14631-08-4 ]

[ 14631-08-4 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 14631-08-4 ]
  • [ 13754-19-3 ]
  • 2
  • [ 1920-66-7 ]
  • [ 14631-08-4 ]
YieldReaction ConditionsOperation in experiment
54.5% With water; iron; ammonium chloride; In ethanol; at 100℃; for 4h; To a solution of compound 21-2 (20 g, 114.6 mmol) in EtOH/H2O (4/1, 400 mL) was added iron powder (64 g, 1146 mmol) and NH4Cl (aq., 62 g, 1146 mmol), the reaction solution was stirred at 100 C. for 4 h, followed by filtration. The filter cake was washed with MeOH (10 mL×3) and the filtrate was concentrated to give compound 21-3 (9 g, Yield 54.5%) as yellow solid.
49% With tin(II) chloride dihdyrate; In ethanol; at 80℃; for 2h;Inert atmosphere; Step-1: 2-chloropyrimidine-4,5-diamine [0176] A mixture of <strong>[1920-66-7]2-chloro-5-nitropyrimidin-4-amine</strong> (1.0 g, 5.7 mmol) and SnCl2·2H2O (5.2 g, 22.9 mmol) in EtOH (55 mL) under N2 was heated to 80 C and stirred for two hours. The mixture was then concentrated under reduced pressure. EtOAc and Celite were added to the residue and the mixture was basified with saturated Na2CO3 (aq.) to pH 9- 10. The mixture was filtered through a pad of Celite and washed with EtOAc. The organic layer was separated and washed with brine, dried (Na2SO4) and concentrated in vacuum. The residue was purified on ISCO (20 g silica gel column, EtOAc/hexanes 0~100%) to give the title compound (0.41 g, 49%).
33% With iron; ammonium chloride; In tetrahydrofuran; ethanol; water;Reflux; General procedure: Commercial 1a (50mmol) was dissolved in dichloromethane (80mL), mixture was cooled to 0C, solution of NH3 in MeOH (4mol/L, 12.5mL) was added by dripping slowly, after 30min, the mixture maintained at 0C for 1h. The reaction mixture was filtered, and the insoluble material was washed with ethyl acetate (20mL) and water (30mL) to get 2a (8.66g), yield 90%. Compound 2a (50mmol) was dissolved in THF (40mL), then absolute ethyl alcohol (20mL), water (20mL), Fe (4eq) and ammonium chloride (2eq) were added. The mixture was refluxed until raw material disappeared. The reaction mixture was filtered and filter liquor was evaporated by reducing pressure to get 3a (2.4g), yield 33%. Compound 3a (17mmol) was dissolved in DMF (30mL), triethylamine (3eq) was added, and acetyl isothiocyanate (1eq) was added by dripping slowly, the mixture was stirred at room temperature for 30min, then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 1.5eq) was added and stirred overnight at room temperature. Pulled the mixture into ice water, using concentrated HCl regulates pH to 1, the mixture was filtered, the residue was dried and washed by water to give 4a (2.0g), yield 60%. Compound 4a (10mmol), 5a/5b/5c/5d/5e (1.2eq), 120mL 1,4-dioxane, 10mL water, Pd(dppf)Cl2 (0.1eq), and NaHCO3 (1eq) were added to a round-bottomed flask, mixture was stirred for 12h at 90C. Solvent was removed by reduced pressure distillation, residue was purified by preparative HPLC (MeCN+0.05% TFA, H2O 0.1%+TFA), Ta-e were finally obtained from above steps, yield 0.58-5.5%.
With water; ammonium chloride;iron; In tetrahydrofuran; ethanol; for 3h;Reflux; (2) The mixture of the above-mentioned product (41 g), reduced iron (52 g), ammonium chloride (25 g), tetrahydrofuran (200 ml), ethanol (100 ml) and water (100 ml) was heated under reflux for 3 hours. The reaction mixture was cooled to room temperature and was filtered through Celite, and ethanol was then evaporated under reduced pressure. The crystals precipitated were collected by filtration and was dried to give 2-chloropyrimidin-4,5-diamine 28 g. 1H-NMR (DMSO-d6) delta: 4.89 (2H, br s), 6.89 (2H, br s), 7.40 (1H, s).

 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 14631-08-4 ]

Chlorides

Chemical Structure| 63211-98-3

A116892 [63211-98-3]

2-Chloro-6-methylpyrimidine-4,5-diamine

Similarity: 0.88

Chemical Structure| 1681-15-8

A114127 [1681-15-8]

2-Chloro-9H-purine

Similarity: 0.81

Chemical Structure| 56621-90-0

A200494 [56621-90-0]

5-Amino-2-chloropyrimidine

Similarity: 0.81

Chemical Structure| 7461-50-9

A461094 [7461-50-9]

2-Chloropyrimidin-4-amine

Similarity: 0.81

Chemical Structure| 66131-68-8

A125024 [66131-68-8]

2-Chloro-N-methylpyrimidin-4-amine

Similarity: 0.75

Amines

Chemical Structure| 63211-98-3

A116892 [63211-98-3]

2-Chloro-6-methylpyrimidine-4,5-diamine

Similarity: 0.88

Chemical Structure| 56621-90-0

A200494 [56621-90-0]

5-Amino-2-chloropyrimidine

Similarity: 0.81

Chemical Structure| 7461-50-9

A461094 [7461-50-9]

2-Chloropyrimidin-4-amine

Similarity: 0.81

Chemical Structure| 66131-68-8

A125024 [66131-68-8]

2-Chloro-N-methylpyrimidin-4-amine

Similarity: 0.75

Chemical Structure| 4316-98-7

A217917 [4316-98-7]

6-Chloro-4,5-diaminopyrimidine

Similarity: 0.74

Related Parent Nucleus of
[ 14631-08-4 ]

Pyrimidines

Chemical Structure| 63211-98-3

A116892 [63211-98-3]

2-Chloro-6-methylpyrimidine-4,5-diamine

Similarity: 0.88

Chemical Structure| 56621-90-0

A200494 [56621-90-0]

5-Amino-2-chloropyrimidine

Similarity: 0.81

Chemical Structure| 7461-50-9

A461094 [7461-50-9]

2-Chloropyrimidin-4-amine

Similarity: 0.81

Chemical Structure| 66131-68-8

A125024 [66131-68-8]

2-Chloro-N-methylpyrimidin-4-amine

Similarity: 0.75

Chemical Structure| 4316-98-7

A217917 [4316-98-7]

6-Chloro-4,5-diaminopyrimidine

Similarity: 0.74